Last reviewed · How we verify

Hib (hib)

Pfizer · FDA-approved approved Quality 59/100

Hib is a bacterial vaccine that stimulates an immune response against Haemophilus influenzae type b.

Pfizer's Hib vaccine holds a significant market position with 51 approved indications, though it is not among the world's best-selling drugs. The vaccine faces competition from alternatives like Rifampin, Rifadin IV, Rimactane, ActHIB, and Haemophilus b conjugate (prp-omp) vaccine, which also target Haemophilus influenzae prophylaxis. A key risk is the requirement for a PD-L1 companion diagnostic for several of its indications, potentially limiting its market reach. Despite the competitive landscape, the robust number of approved indications suggests a strong pipeline outlook for the vaccine.

At a glance

Generic namehib
SponsorPfizer
Drug classbacterial vaccine
TargetHaemophilus influenzae type b
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Haemophilus influenzae is a Gram-negative, non-motile, coccobacillary, facultatively anaerobic, capnophilic pathogenic bacterium of the family Pasteurellaceae. The bacteria are mesophilic and grow best at temperatures between 35 and 37 °C. This bacterium is responsible for causing Haemophilus influenzae type b disease in children.

Approved indications

Common side effects

Drug interactions